中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 3
Mar.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(3): 649-652

Research advances in hepatitis D

DOI: 10.3969/j.issn.1001-5256.2022.03.032

  • Fourth Department of Liver Disease Center, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Research funding:

Project of Advanced Innovation Center for Big Data-Based Precision Medicine (1212040205);

National Natural Science Foundation of China (81770611);

Key Project Jointly Funded by Beijing Natural Science Foundation and Beijing Municipal Commission of Education (KZ202010025035)

More Information
  • Corresponding author: DUAN Zhongping, duan@ccmu.edu.cn(ORCID:0000-0002-8455-0426)
  • Received Date: 2021-07-26
  • Accepted Date: 2021-08-10
  • Published Date: 2022-03-20
    Abstract
  • Hepatitis D virus (HDV) needs hepatitis B virus (HBV) as a helper to infect hepatocytes and spread. Co-infection with HDV and HBV may lead to accelerated progression and poor prognosis, but at present, the hazard and disease burden of HDV infection have been severely underestimated. This article summarizes the research advances in the epidemiology, clinical manifestations, diagnosis, and treatment of HDV infection, in order to provide a reference for more clinicians.

     

    • FullText(HTML)
  • loading
    • References(52)
  • [1]
    RIZZETTO M, CANESE MG, ARICÒ S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers[J]. Gut, 1977, 18(12): 997-1003. DOI: 10.1136/gut.18.12.997.
    [2]
    BOTELHO-SOUZA LF, VASCONCELOS M, DOS SANTOS AO, et al. Hepatitis delta: Virological and clinical aspects[J]. Virol J, 2017, 14(1): 177. DOI: 10.1186/s12985-017-0845-y.
    [3]
    HUGHES SA, WEDEMEYER H, HARRISON PM. Hepatitis delta virus[J]. Lancet, 2011, 378(9785): 73-85. DOI: 10.1016/S0140-6736(10)61931-9.
    [4]
    URBAN S, NEUMANN-HAEFELIN C, LAMPERTICO P. Hepatitis D virus in 2021: Virology, immunology and new treatment approaches for a difficult-to-treat disease[J]. Gut, 2021, 70(9): 1782-1794. DOI: 10.1136/gutjnl-2020-323888.
    [5]
    BESOMBES C, NJOUOM R, PAIREAU J, et al. The epidemiology of hepatitis delta virus infection in Cameroon[J]. Gut, 2020, 69(7): 1294-1300. DOI: 10.1136/gutjnl-2019-320027.
    [6]
    TOY M, AHISHALI E, YURDAYD1N C. Hepatitis delta virus epidemiology in the industrialized world[J]. AIDS Rev, 2020, 22(4): 203-212. DOI: 10.24875/AIDSRev.20000056.
    [7]
    LEMPP FA, NI Y, URBAN S. Hepatitis delta virus: Insights into a peculiar pathogen and novel treatment options[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(10): 580-589. DOI: 10.1038/nrgastro.2016.126.
    [8]
    STOCKDALE AJ, KREUELS B, HENRION M, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis[J]. J Hepatol, 2020, 73(3): 523-532. DOI: 10.1016/j.jhep.2020.04.008.
    [9]
    ZHANG Z, URBAN S. New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies[J]. J Hepatol, 2021, 74(3): 686-699. DOI: 10.1016/j.jhep.2020.11.032.
    [10]
    CHEN HY, SHEN DT, JI DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: A systematic review and meta-analysis[J]. Gut, 2019, 68(3): 512-521. DOI: 10.1136/gutjnl-2018-316601.
    [11]
    MIAO Z, ZHANG S, OU X, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection[J]. J Infect Dis, 2020, 221(10): 1677-1687. DOI: 10.1093/infdis/jiz633.
    [12]
    SHEN DT, JI DZ, CHEN HY, et al. Hepatitis D: Not a rare disease anymore: Global update for 2017-2018[J]. Gut, 2020, 69(4): 786-788. DOI: 10.1136/gutjnl-2019-318691.
    [13]
    WU S, ZHANG Y, TANG Y, et al. Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with elevated transaminases in Shanghai, China[J]. BMC Infect Dis, 2020, 20(1): 565. DOI: 10.1186/s12879-020-05275-1.
    [14]
    ROULOT D, BRICHLER S, LAYESE R, et al. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta[J]. J Hepatol, 2020, 73(5): 1046-1062. DOI: 10.1016/j.jhep.2020.06.038.
    [15]
    HERCUN J, KOH C, HELLER T. Hepatitis delta: Prevalence, natural history, and treatment options[J]. Gastroenterol Clin North Am, 2020, 49(2): 239-252. DOI: 10.1016/j.gtc.2020.01.004.
    [16]
    DIAS J, HENGST J, PARROT T, et al. Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells[J]. J Hepatol, 2019, 71(2): 301-312. DOI: 10.1016/j.jhep.2019.04.009.
    [17]
    THAM C, KAH J, TAN AT, et al. Hepatitis delta virus acts as an immunogenic adjuvant in hepatitis B virus-infected hepatocytes[J]. Cell Rep Med, 2020, 1(4): 100060. DOI: 10.1016/j.xcrm.2020.100060.
    [18]
    VIEIRA BARBOSA J, SAHLI R, AUBERT V, et al. Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center[J]. PLoS One, 2021, 16(4): e0250347. DOI: 10.1371/journal.pone.0250347.
    [19]
    SAGNELLI C, SAGNELLI E, RUSSO A, et al. HBV/HDV co-infection: Epidemiological and clinical changes, recent knowledge and future challenges[J]. Life (Basel), 2021, 11(2): 169. DOI: 10.3390/life11020169.
    [20]
    BRICHLER S, LE GAL F, BUTT A, et al. Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia[J]. Clin Gastroenterol Hepatol, 2013, 11(6): 734-740. DOI: 10.1016/j.cgh.2013.01.025.
    [21]
    LU XX, YI Y, SU QD, et al. Expression and purification of recombinant hepatitis delta virus (HDV) antigen for use in a diagnostic ELISA for HDV infection using the high-density fermentation strategy in Escherichia coli[J]. Biomed Environ Sci, 2016, 29(6): 417-423. DOI: 10.3967/bes2016.054.
    [22]
    CHEN X, OIDOVSAMBUU O, LIU P, et al. A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians[J]. Hepatology, 2017, 66(6): 1739-1749. DOI: 10.1002/hep.28957.
    [23]
    CHEN GH, ZHANG MD, HUANG W. Hepatitis delta virus superinfection in Guangzhou area[J]. Chin Med J (Engl), 1990, 103(6): 451-454. http://www.ncbi.nlm.nih.gov/pubmed/2119957
    [24]
    JIANG YZ, ZHANG MC, TIAN RG, et al. Expression of the hepatitis Delta antigen in prokaryotic cell and evaluation of its application as an EIA diagnostic reagent[J]. Chin J Exp Clin Virol, 2006, 20(2): 38-41. DOI: 10.3760/cma.j.issn.1003-9279.2006.02.012.

    江永珍, 张明程, 田瑞光, 等. 丁型肝炎病毒抗原的原核表达及抗原性分析[J]. 中华实验和临床病毒学杂志, 2006, 20(2): 38-41. DOI: 10.3760/cma.j.issn.1003-9279.2006.02.012.
    [25]
    SHEN L, GU Y, SUN L, et al. Development of a hepatitis delta virus antibody assay for study of the prevalence of HDV among individuals infected with hepatitis B virus in China[J]. J Med Virol, 2012, 84(3): 445-449. DOI: 10.1002/jmv.23212.
    [26]
    GU WJ, HUANG WJ, ZHOU C, et al. Evaluate the HDV diagnostic kits (EIA) with HBV surface antigen positive sera[J]. Chin Pharm Affairs, 2011, 25(9): 866-868, 879. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYS201109009.htm

    辜文洁, 黄维金, 周诚, 等. 不同HDV诊断试剂对HBsAg阳性样品的检测分析[J]. 中国药事, 2011, 25(9): 866-868, 879. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYS201109009.htm
    [27]
    TAYLOR JM. Infection by hepatitis delta virus[J]. Viruses, 2020, 12(6): 648. DOI: 10.3390/v12060648.
    [28]
    LIN GY, WU YL, WANG CS, et al. Performance of commercially available anti-HDV enzyme-linked immunosorbent assays in Taiwan[J]. Virol J, 2020, 17(1): 76. DOI: 10.1186/s12985-020-01355-5.
    [29]
    STELZL E, CIESEK S, CORNBERG M, et al. Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study[J]. J Clin Virol, 2021, 142: 104932. DOI: 10.1016/j.jcv.2021.104932.
    [30]
    KOH C, HELLER T, GLENN JS. Pathogenesis of and new therapies for hepatitis D[J]. Gastroenterology, 2019, 156(2): 461-476. DOI: 10.1053/j.gastro.2018.09.058.
    [31]
    BATTEGAY M, SIMPSON LH, HOOFNAGLE JH, et al. Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis[J]. J Med Virol, 1994, 44(4): 389-392. DOI: 10.1002/jmv.1890440413.
    [32]
    FARCI P, MANDAS A, COIANA A, et al. Treatment of chronic hepatitis D with interferon alfa-2a[J]. N Engl J Med, 1994, 330(2): 88-94. DOI: 10.1056/NEJM199401133300202.
    [33]
    CASTELNAU C, LE GAL F, RIPAULT MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up[J]. Hepatology, 2006, 44(3): 728-735. DOI: 10.1002/hep.21325.
    [34]
    ABDRAKHMAN A, ASHIMKHANOVA A, ALMAWI WY. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis[J]. Antiviral Res, 2021, 185: 104995. DOI: 10.1016/j.antiviral.2020.104995.
    [35]
    SHELDON J, RAMOS B, TORO C, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?[J]. Antivir Ther, 2008, 13(1): 97-102. http://med.wanfangdata.com.cn/DocDeliveryNstl/Index/PeriodicalPaper_JJ024367317
    [36]
    YURDAYDIN C, BOZKAYA H, ONDER FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine+interferon vs interferon[J]. J Viral Hepat, 2008, 15(4): 314-321. DOI: 10.1111/j.1365-2893.2007.00936.x.
    [37]
    KABAÇAM G, ONDER FO, YAKUT M, et al. Entecavir treatment of chronic hepatitis D[J]. Clin Infect Dis, 2012, 55(5): 645-650. DOI: 10.1093/cid/cis459.
    [38]
    WEDEMEYER H, YURDAYDÌN C, DALEKOS GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta[J]. N Engl J Med, 2011, 364(4): 322-331. DOI: 10.1056/NEJMoa0912696.
    [39]
    ABBAS Z, MEMON MS, UMER MA, et al. Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial[J]. World J Hepatol, 2016, 8(14): 625-631. DOI: 10.4254/wjh.v8.i14.625.
    [40]
    WEDEMEYER H, YURDAYDIN C, HARDTKE S, et al. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-Ⅱ): A randomised, placebo controlled, phase 2 trial[J]. Lancet Infect Dis, 2019, 19(3): 275-286. DOI: 10.1016/S1473-3099(18)30663-7.
    [41]
    BOGOMOLOV P, ALEXANDROV A, VORONKOVA N, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study[J]. J Hepatol, 2016, 65(3): 490-498. DOI: 10.1016/j.jhep.2016.04.016.
    [42]
    LOGLIO A, FERENCI P, UCEDA RENTERIA SC, et al. Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients[J]. J Hepatol, 2019, 71(4): 834-839. DOI: 10.1016/j.jhep.2019.07.003.
    [43]
    WEDEMEYER H, SCHÖNEWEIS K, BOGOMOLOV P, et al. 48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection[J]. J Hepatol, 2020, 73(Suppl 1): s52-s53. http://www.sciencedirect.com/science/article/pii/S0168827820306516
    [44]
    CHAN H, AHN SH, CHANG TT, et al. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)[J]. J Hepatol, 2016, 64(5): 1011-1019. DOI: 10.1016/j.jhep.2015.12.018.
    [45]
    ETZION O, HAMID S, LURIE Y, et al. End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection[J]. J Hepatol, 2019, 70(Suppl 1): e32.
    [46]
    KOH C, HERCUN J, RAHMAN F, et al. A phase 2 study of peginterferon lambda, lonafarnib and ritonavir for 24 weeks: End-of-treatment results from the lift HDV study[J]. J Hepatol, 2020, 73: s130. http://www.sciencedirect.com/science/article/pii/S0168827820307741
    [47]
    BALDRIDGE MT, LEE S, BROWN JJ, et al. Expression of Ifnlr1 on intestinal epithelial cells is critical to the antiviral effects of interferon lambda against norovirus and reovirus[J]. J Virol, 2017, 91(7): e02079-16. DOI: 10.1128/JVI.02079-16.
    [48]
    KOH C, CANINI L, DAHARI H, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: A proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial[J]. Lancet Infect Dis, 2015, 15(10): 1167-1174. DOI: 10.1016/S1473-3099(15)00074-2.
    [49]
    BERNDT N, HAMILTON AD, SEBTI SM. Targeting protein prenylation for cancer therapy[J]. Nat Rev Cancer, 2011, 11(11): 775-791. DOI: 10.1038/nrc3151.
    [50]
    YURDAYDIN C, KESKIN O, KALKAN Ç, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study[J]. Hepatology, 2018, 67(4): 1224-1236. DOI: 10.1002/hep.29658.
    [51]
    BEILSTEIN F, BLANCHET M, VAILLANT A, et al. Nucleic acid polymers are active against hepatitis delta virus infection in vitro[J]. J Virol, 2018, 92(4): e01416-17. DOI: 10.1128/JVI.01416-17.
    [52]
    VAILLANT A. REP 2139: Antiviral mechanisms and applications in achieving functional control of HBV and HDV infection[J]. ACS Infect Dis, 2019, 5(5): 675-687. DOI: 10.1021/acsinfecdis.8b00156.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (712) PDF downloads(110) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return